PRDM2

Across TCGA pan-cancer cohorts, PRDM2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRDM2 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PRDM2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRDM2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

LSCC, UCEC, and PDAC are the cancer types where PRDM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.828	0.508	.001	39	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.361	.005	24	view →
PDAC	DFS	Quartile	II,III,IV	0.372	0.728	.012	9	view →
HNSC	DFS	Median	All	0.984	0.899	.003	6	view →
GBM	DFS	Tertile	All	0.298	0.468	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRDM2–LSCC (DFS)

Open the LSCC breakdown →